← Leaderboards
Tonia S Rex
University Of Tennessee Health Sci Ctr
$6,360,522
Attributed
$12,067,661
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2012–25$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,067,661 · 5
By mechanism
U24$7,152,243 · 1
R01$4,748,623 · 2
P30$166,795 · 2
Top collaborators
- Petr Baranov6 shared
- David J Calkins6 shared
- Brian Christopher Samuels6 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Monica M Jablonski$8,426,014
- Dianna Ammons Johnson$4,714,453
Others in their field
Top investigators on “Vision”
- Chanza Baytop · Westat, Inc.$271,217,917
- Edward W Maly · United Nations Children'S Fund$264,005,699
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Everette D Joseph · Howard University$243,972,016
Research focus
VisionBaseAxonOptic NerveRetinaAstrocytesGlaucomaPhysiologic Intraocular PressureCellsInjuryMouse ModelDiagnosisRetinal Ganglion CellsResponseBlindnessHistologyPreservationMicrospheresErythropoietinBrainImmunohistochemistryProteinsSynapsesOptic Disk
Grant awards (26)
Mitochondria: controllers of trauma-induced secondary neurodegeneration onset$480,156
R01 · FY2025 · EY · contact PI
Mitochondria: controllers of trauma-induced secondary neurodegeneration onset$477,794
R01 · FY2024 · EY · contact PI
Genomics Core$33,359
P30 · FY2023 · EY · contact PI
Retinal Ganglion Cell Replacement in Clinically Relevant Models of Optic Neuropathy$1,330,471
U24 · FY2022 · EY · contact PI
Genomics Core$33,359
P30 · FY2022 · EY · contact PI
Retinal Ganglion Cell Replacement in Clinically Relevant Models of Optic Neuropathy$1,346,020
U24 · FY2021 · EY · contact PI
Erythropoietin-mediated antioxidant pathways in glaucoma$421,140
R01 · FY2021 · EY · contact PI
Retinal Ganglion Cell Replacement in Clinically Relevant Models of Optic Neuropathy$350,000
U24 · FY2021 · EY · contact PI
Role of the Nrf2/ARE pathway in retinal ganglion cells during glaucoma pathogenesis and neuroprotection$59,624
R01 · FY2021 · EY · contact PI
Erythropoietin-mediated antioxidant pathways in glaucoma$57,835
R01 · FY2021 · EY · contact PI
Genomics Core$33,359
P30 · FY2021 · EY · contact PI
Retinal Ganglion Cell Replacement in Clinically Relevant Models of Optic Neuropathy$1,380,699
U24 · FY2020 · EY · contact PI
Erythropoietin-mediated antioxidant pathways in glaucoma$438,495
R01 · FY2020 · EY · contact PI
Genomics Core$33,359
P30 · FY2020 · EY · contact PI
Retinal Ganglion Cell Replacement in Clinically Relevant Models of Optic Neuropathy$1,367,940
U24 · FY2019 · EY · contact PI
Erythropoietin-mediated antioxidant pathways in glaucoma$443,971
R01 · FY2019 · EY · contact PI
Genomics Core$33,359
P30 · FY2019 · EY · contact PI
Retinal Ganglion Cell Replacement in Clinically Relevant Models of Optic Neuropathy$1,377,113
U24 · FY2018 · EY · contact PI
Erythropoietin-mediated antioxidant pathways in glaucoma$456,890
R01 · FY2018 · EY · contact PI
Novel Therapy and Mechanisms in Glaucoma$378,539
R01 · FY2016 · EY · contact PI
Novel Therapy and Mechanisms in Glaucoma$11,461
R01 · FY2016 · EY · contact PI
Novel Therapy and Mechanisms in Glaucoma$382,200
R01 · FY2015 · EY · contact PI
Novel Therapy and Mechanisms in Glaucoma$382,200
R01 · FY2014 · EY · contact PI
Novel Therapy and Mechanisms in Glaucoma$370,500
R01 · FY2013 · EY · contact PI
Novel Therapy and Mechanisms in Glaucoma$343,583
R01 · FY2012 · EY · contact PI
Novel Therapy and Mechanisms in Glaucoma$44,235
R01 · FY2012 · EY · contact PI